GlassScriptPhysician profile
Suellyn S Rossman
NPI 1790773216
$22,617.82
in general payments reported to CMS, 2019-2025
23 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,501 · 2020: $1,260 · 2021: $1,186 · 2022: $1,315 · 2023: $7,110 · 2024: $1,065 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,450 · Food and Beverage: $3,379 · Travel and Lodging: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,450.00 |
| Food and Beverage | $3,378.98 |
| Travel and Lodging | $527.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,607.19 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genentech, INC. | $3,977.52 | 2023 | Xolair |
| Abbvie INC. | $2,211.42 | 2021-2024 | Ubrelvy |
| Genentech USA, INC. | $1,131.67 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $1,044.47 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $967.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $803.91 | 2019-2025 | |
| Optinose US, INC. | $433.84 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $279.68 | 2025 | |
| Amgen INC. | $265.83 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.45 | 2019-2020 | |
| Pfizer INC. | $197.11 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $99.31 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $62.79 | 2019 | |
| Viatris Specialty LLC | $60.01 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $58.39 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $41.00 | 2019 | |
| Kaleo, INC. | $35.81 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $26.93 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $20.73 | 2022 | |
| Uswm, LLC | $17.28 | 2021 | |
| Greer Laboratories, INC. | $16.23 | 2019 | |
| Merck Sharp & Dohme LLC | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suellyn Rossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.